Inflammatix develops rapid immune system diagnostics to improve patient care and public health.
Inflammatix has raised $57.0M in total funding. The most recent round was Series E. The last funding was announced in September 2024.
Inflammatix's investors include Khosla Ventures, National Institutes of Health, OSF Ventures, Northpond Ventures, Vesalius Biocapital Partners.
Inflammatix is headquartered in Burlingame, United States.
Inflammatix develops rapid immune system diagnostics to improve patient care and public health.
Inflammatix is at the Series E stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Inflammatix — Funding & Investors." VCBacked, September 12, 2024, https://www.vcbacked.co/company/inflammatix. Accessed September 3, 2026.
VCBacked. (2024). Inflammatix — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/inflammatix
{{cite web |title=Inflammatix — Funding & Investors |url=https://www.vcbacked.co/company/inflammatix |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated